On May 31, 2018, Hansoh’s Xinwei (Imatinib Mesylate Tablets) was approved by National Medical Products Administration (“NMPA”) and passed the quality and efficacy consistency evaluation of generic drugs. We are the first to pass the consistency evaluation of Imatinib Mesylate Tablets.

Imatinib mesylate is a small molecule oncology drug, mainly used for targeted therapy of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia gastrointestinal stromal tumors, etc.